FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590613491> ?p ?o ?g. }

• W2590613491 abstract "Abstract Abstract 2624 The incidence of acute myeloid leukemia (AML) increases with age and outcomes for elderly patients remain poor. Furthermore, intensive induction chemotherapy is often unsuitable for elderly patients and can result in significant periods of inpatient care. Recent understanding of leukemia stem cell cycling suggests that prolonged cytotoxic exposure, e.g. >14–21 days, could provide a more effective anti-leukemic effect than the typical 5–7 days schedules during which time very few leukemic stem cells would be likely to undergo cell division. We have been using prolonged low-dose cytarabine schedules as reported 20 years ago (Hellstrom-Lindberg, Brit J Haem,1992;81:503), however we have combined this with oral thioguanine, a purine analogue that may synergize with cytarabine. Concomitant filgrastim or pegfilgrastim was given to minimize neutropenia and for its possible synergizing anti-leukemic effect when combined with cytotoxic agents. Encouraging experience with this schedule in a few relapsed/refractory elderly AML patients prompted us to use this strategy in elderly de-novo patients unsuitable for standard induction. Surprisingly good results prompted us to report our preliminary experience with this novel strategy. This report is a retrospective, single-center analysis of outcomes in elderly patients with AML managed as outpatients in an ambulatory care day unit. Between April 2009 and March 2011, 14 patients with either relapsed/refractory AML (n=5) or de novo AML (n=9) unsuitable for intensive therapy were treated using prolonged, low-dose cytarabine 20mg/m2/day subcutaneously and thioguanine 80mg/day orally. Treatment was given for 21 days followed by a 14 day break after which the schedule was repeated until remission. After obtaining remission, patients received a maintenance schedule consisting of 14 days on treatment with rest periods increasing from 14 to 28 days according to tolerance and time on therapy, with an intention to continue maintenance for 2 years. All patients received the treatment in an ambulatory care unit with supportive care including filgrastim or pegfilgrastim, blood and platelet transfusion as required, regular clinical review and prophylactic antibiotics and antifungal agents. Patient age ranged from 52 to 89 years (median 75y). All patients had intermediate or poor risk cytogenetics. A morphologic remission according to bone marrow aspirate was obtained in 8 patients (57.1%), with relapse seen in 1 patient at 2.6 months follow-up. Remission was maintained in 7 patients (50%) with follow-up ranging from 4.7 to 26.6 months (median 9.7 months), including 1 patient who was refractory to standard first and second-line induction chemotherapy. Refractoriness to treatment occurred in 5 patients (35.7%). Mortality relating to disease progression occurred in 3 patients (21.4%) and 1 patient died secondary to infection. All patients developed grade 3/4 neutropenia and thrombocytopenia but severe mucositis was not seen. The infection rate was low and hospital admission was uncommon. Nausea was common but manageable and significant liver toxicity was not observed. This study demonstrates that effective management of AML in elderly patients can be achieved in the outpatient setting. The data suggests a surprising efficacy for this strategy, with a remission rate comparable to that reported using standard induction chemotherapy but with a potentially favorable toxicity profile. A prospective study is now underway to further evaluate this protocol. Disclosures: Arthur: AMGEN: Honoraria." @default.
• W2590613491 created "2017-03-03" @default.
• W2590613491 creator A5007181936 @default.
• W2590613491 creator A5014020758 @default.
• W2590613491 creator A5023882247 @default.
• W2590613491 creator A5036455020 @default.
• W2590613491 creator A5042160081 @default.
• W2590613491 creator A5044831223 @default.
• W2590613491 creator A5052770823 @default.
• W2590613491 creator A5065225093 @default.
• W2590613491 creator A5065361516 @default.
• W2590613491 creator A5090765886 @default.
• W2590613491 date "2011-11-18" @default.
• W2590613491 modified "2023-09-30" @default.
• W2590613491 title "High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study" @default.
• W2590613491 doi "https://doi.org/10.1182/blood.v118.21.2624.2624" @default.
• W2590613491 hasPublicationYear "2011" @default.
• W2590613491 type Work @default.
• W2590613491 sameAs 2590613491 @default.
• W2590613491 citedByCount "0" @default.
• W2590613491 crossrefType "journal-article" @default.
• W2590613491 hasAuthorship W2590613491A5007181936 @default.
• W2590613491 hasAuthorship W2590613491A5014020758 @default.
• W2590613491 hasAuthorship W2590613491A5023882247 @default.
• W2590613491 hasAuthorship W2590613491A5036455020 @default.
• W2590613491 hasAuthorship W2590613491A5042160081 @default.
• W2590613491 hasAuthorship W2590613491A5044831223 @default.
• W2590613491 hasAuthorship W2590613491A5052770823 @default.
• W2590613491 hasAuthorship W2590613491A5065225093 @default.
• W2590613491 hasAuthorship W2590613491A5065361516 @default.
• W2590613491 hasAuthorship W2590613491A5090765886 @default.
• W2590613491 hasConcept C126322002 @default.
• W2590613491 hasConcept C143998085 @default.
• W2590613491 hasConcept C2776611710 @default.
• W2590613491 hasConcept C2776694085 @default.
• W2590613491 hasConcept C2777063308 @default.
• W2590613491 hasConcept C2778041864 @default.
• W2590613491 hasConcept C2778461978 @default.
• W2590613491 hasConcept C2778729363 @default.
• W2590613491 hasConcept C2778850193 @default.
• W2590613491 hasConcept C2779171977 @default.
• W2590613491 hasConcept C2780923524 @default.
• W2590613491 hasConcept C71924100 @default.
• W2590613491 hasConcept C90924648 @default.
• W2590613491 hasConceptScore W2590613491C126322002 @default.
• W2590613491 hasConceptScore W2590613491C143998085 @default.
• W2590613491 hasConceptScore W2590613491C2776611710 @default.
• W2590613491 hasConceptScore W2590613491C2776694085 @default.
• W2590613491 hasConceptScore W2590613491C2777063308 @default.
• W2590613491 hasConceptScore W2590613491C2778041864 @default.
• W2590613491 hasConceptScore W2590613491C2778461978 @default.
• W2590613491 hasConceptScore W2590613491C2778729363 @default.
• W2590613491 hasConceptScore W2590613491C2778850193 @default.
• W2590613491 hasConceptScore W2590613491C2779171977 @default.
• W2590613491 hasConceptScore W2590613491C2780923524 @default.
• W2590613491 hasConceptScore W2590613491C71924100 @default.
• W2590613491 hasConceptScore W2590613491C90924648 @default.
• W2590613491 hasLocation W25906134911 @default.
• W2590613491 hasOpenAccess W2590613491 @default.
• W2590613491 hasPrimaryLocation W25906134911 @default.
• W2590613491 hasRelatedWork W1509346046 @default.
• W2590613491 hasRelatedWork W1546635264 @default.
• W2590613491 hasRelatedWork W1616474014 @default.
• W2590613491 hasRelatedWork W2016395017 @default.
• W2590613491 hasRelatedWork W2050782849 @default.
• W2590613491 hasRelatedWork W2186232402 @default.
• W2590613491 hasRelatedWork W2530685841 @default.
• W2590613491 hasRelatedWork W2566033835 @default.
• W2590613491 hasRelatedWork W2570224382 @default.
• W2590613491 hasRelatedWork W2572092593 @default.
• W2590613491 hasRelatedWork W2579802222 @default.
• W2590613491 hasRelatedWork W2588178043 @default.
• W2590613491 hasRelatedWork W2589503393 @default.
• W2590613491 hasRelatedWork W2596206182 @default.
• W2590613491 hasRelatedWork W2754778309 @default.
• W2590613491 hasRelatedWork W2911669613 @default.
• W2590613491 hasRelatedWork W2980959171 @default.
• W2590613491 hasRelatedWork W2987113991 @default.
• W2590613491 hasRelatedWork W3003909887 @default.
• W2590613491 hasRelatedWork W3030815057 @default.
• W2590613491 isParatext "false" @default.
• W2590613491 isRetracted "false" @default.
• W2590613491 magId "2590613491" @default.
• W2590613491 workType "article" @default.